Biomarkers, Diagnostic Tools, Treatment Outcomes, and Late Complications in Neuro-Oncology

Dear Colleagues, 

Neuro-oncology has seen major advances in diagnostics and targeted therapies, particularly in pediatric brain tumors. Classification of tumors has changed dramatically, and the community is adapting to a wide range of pharmacological agents not previously used in oncology. It is important that biomarkers and diagnostic tools are developed and used to assess and predict treatment outcomes and, for long-term survivors, late complications, also called late effects.

The topic of this Special Issue is the advancement of biomarkers and diagnostic tools to complement the classical tools at hand, thereby hopefully providing a better basis for treatment decisions, when to start, what to use, and for how long. The same biomarkers and diagnostic tools may also provide important information on the risk of developing so-called late effects, nowadays more commonly termed late complications, and their severity. There is a great lack of research in this field, where the aim is to understand why late complications occur, and how they can be prevented, or even reversed. The goal must be to not only ensure patients survive, but also retain their quality of life.

The aim of this issue is, on the one hand, to promote investigations on biomarkers and diagnostic tools that enable better treatment decisions and, on the other hand, to promote investigation into the other end of the spectrum—the quality of life of long-term survivors, particularly in pediatric neuro-oncology.

Prof. Dr. Klas Blomgren
Dr. Adamantia Fragopoulou
Dr. Lena-Maria Carlson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.